SOURCE: Callisto Pharmaceuticals, Inc.

May 11, 2005 08:30 ET

Callisto Pharmaceuticals Announces Poster on Atiprimod at American Society of Clinical Oncology Conference

NEW YORK, NY -- (MARKET WIRE) -- May 11, 2005 -- Callisto Pharmaceuticals, Inc. (AMEX: KAL), a biopharmaceutical company primarily focused on the development of drugs to treat cancer, today announced that a poster entitled "In vivo activity of Atiprimod on SCID models of Multiple Myeloma" will be presented at the American Society of Clinical Oncology conference on May 13-17 at the Orange County Convention Center in Orlando, FL. The poster (abstract #6603, poster #B13), authored by P. Neri(1), P. Tassone(1), M. Shammas(1), R. B. Batchu(1), M. Hamasaki(1), T. Hideshima(1), L. Catley(1), G. S. Jacob(2), D. Picker(2), S.Venuta(1), K.C. Anderson(1) and N.C. Munshi(1) ((1)Dana-Farber Cancer Institute, Boston, MA; (2)Callisto Pharmaceuticals, Inc., NY, NY) will be presented on Tuesday, May 17th, from 8 am to 12 noon in Hall C level 2.

Atiprimod is Callisto's drug candidate for treatment of multiple myeloma, and is presently being evaluated in a Phase I/IIa clinical trial in relapsed multiple myeloma patients at four leading cancer centers in the United States, the Dana-Farber Cancer Institute in Boston, Massachusetts, the University of Texas M. D. Anderson Cancer Center, Houston, Texas, the Roswell Park Cancer Institute in Buffalo, New York and the St. Vincent's Comprehensive Cancer Center in New York, NY.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company primarily focused on the development of drugs to treat cancer. Callisto has two lead drugs in clinical development, Annamycin to treat relapsed leukemia, and Atiprimod to treat relapsed multiple myeloma. Callisto intends to initiate a Phase IIb clinical trial of Annamycin in relapsed acute lymphoblastic leukemia patients in mid 2005. Annamycin, a drug from the anthracycline family, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity. Callisto's second drug, Atiprimod, is in a Phase I/IIa clinical trial in relapsed multiple myeloma patients, and is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity. Callisto also has drugs in preclinical development for melanoma, gastrointestinal inflammation, and a program focused on the development of a drug to protect against staphylococcus and streptococcus biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and Annamycin, respectively. For additional information, visit www.callistopharma.com.

Contact Information